1 week Ago By Defense World Staff
Masimo Co. ( NASDAQ:MASI – Get Free Report ) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports.
Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $179.67.
Several equities research analysts recently weighed in on MASI shares. Piper Sandler upped their target price on shares of Masimo from $180.00 to $210.
00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday. Raymond James lifted their target price on Masimo from $170.
00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Stifel Nicolaus restated a “buy” rating and set a $190.
00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Wells Fargo & Company lifted their price objective on Masimo from $171.
00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Get Our Latest Stock Analysis on MASI Masimo Stock Up 1.
3 % Masimo ( NASDAQ:MASI – Get Free Report ) last posted its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.
84 by $0.14. The firm had revenue of $504.
60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.
98% and a net margin of 3.85%. Masimo’s revenue was up 5.
4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 EPS.
Research analysts predict that Masimo will post 4.1 EPS for the current year. Institutional Trading of Masimo A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MASI.
ING Groep NV grew its position in shares of Masimo by 143.3% in the 3rd quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock valued at $32,119,000 after buying an additional 141,900 shares during the last quarter.
Westfield Capital Management Co. LP boosted its stake in Masimo by 23.2% in the third quarter.
Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after acquiring an additional 262,370 shares in the last quarter. National Bank of Canada FI grew its holdings in shares of Masimo by 195.
6% during the third quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider’s stock worth $17,666,000 after purchasing an additional 87,675 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Masimo during the third quarter worth about $3,862,000.
Finally, Oppenheimer Asset Management Inc. purchased a new stake in shares of Masimo in the 3rd quarter valued at about $478,000. Institutional investors and hedge funds own 85.
96% of the company’s stock. Masimo Company Profile ( Get Free Report Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
See Also Five stocks we like better than Masimo Comparing and Trading High PE Ratio Stocks Bloom Energy: Powering the Future With Decentralized Energy Dividend Payout Ratio Calculator Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul Overbought Stocks Explained: Should You Trade Them? Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter ..
